SPHK1 and melanoma: SPHK1 inhibitors (e.g., PF-543) and S1P receptor modulators (e.g., fingolimod) restore ceramide-mediated apoptosis and reduce T-cell exhaustion, improving the melanoma response to immunotherapies [235].